Salute e Benessere
Syngene International invests in dedicated peptide laboratory and advanced automation
The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and supports synthesis scale-up to 800 mmol (millimole With six automated peptide synthesizers operating in parallel and equipped with robotic arms, the lab reduces project timelines by weeks or even months while ensuring consistent results. It also features integrated Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid Chromatography (HPLC), and Liquid-Phase purification, and coupled with Quality Control (QC) laboratories provide innovators with a seamless transition from discovery to development.
In parallel, Syngene has made an automation-driven transformation in the DMPK operations. The automation includes Robotic systems for high-throughput sample preparation that reduces turnaround times from five days to three and improves cost efficiency by 30%, and triples sample capacities, providing clients access to critical data much faster. The D2B platform further accelerates hit-to-lead and lead optimization by combining rapid compound design, miniaturized synthesis, and high-throughput screening — saving at least a week for 24-compound sets and several weeks for larger sets.
By combining advanced automation with deep scientific expertise, Syngene has built a robust, end-to-end platform that connects discovery to downstream development and manufacturing, strengthening its collaborative model and delivering greater value to clients across the globe.
Syngene International Ltd. (BSE: 539268) (NSE: SYNGENE) (ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit Syngene ESG Report
E: Shotorupa.ghosh@syngeneintl.com
E: Vijay.jeevanandham@syngeneintl.com
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk
Logo - https://mma.prnewswire.com/media/2637918/5569067/Syngene_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/syngene-international-invests-in-dedicated-peptide-laboratory-and-advanced-automation-302587674.html